<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">


Press Releases

Our latest announcements

Biodesix Advances ORACLE Registry for Lung Nodule Cancer Test

Biodesix provided an update on the Observational Registry study to evaluate the impact of BDX-XL2 on physician decision making in routine clinical use (ORACLE)

Biodesix Presents Positive Data in Detection of Primary Immunotherapy Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer

Biodesix presented positive data for a blood-based test with the potential to detect a non-small cell lung cancer (NSCLC) patient’s pre-treatment risk of anti-PD-1 immunotherapy resistance

Biodesix Pipeline Test Demonstrates Utility in Triaging Patients with Lung Nodules in New CHEST Data Publication

Biodesix announced newly published data showing the noninvasive BDX-XL2 test could reduce the number of unnecessary biopsies carried out on patients with benign nodules

Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer

A new study published in the Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell lung cancer

Biodesix Extends Lung Franchise with Acquisition of Integrated Diagnostics

Biodesix announced that it has acquired Integrated Diagnostics, Inc.

Society for Advanced Bronchoscopy Commits to Enhance Education and Practice Excellence as U.S. Demand for Bronchoscopy Procedures Increases

Bronchoscopy professionals in the United States need greater educational and practice-building support to ensure continued delivery of high-quality care for Americans

Society for Advanced Bronchoscopy Meets May 20 to Address “Hot Topics in Advanced Bronchoscopy"

The Society for Advanced Bronchoscopy (SAB) will hold its second meeting: Hot Topics in Advanced Bronchoscopy.

New Data Demonstrate the Biodesix VeriStrat® Liquid Biopsy Test Reliably Informs Lung Cancer Treatment Decisions

New data demonstrate that a blood-based proteomic test reliably assesses individual patient prognosis to inform treatment decisions.

Biodesix Announces Biomarker Research Collaboration with Checkmate Pharmaceuticals

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Biodesix Raises Add-On to Series G, Enters into Debt Refinancing Agreement with Innovatus Capital Partners; Scott Hutton Joins Biodesix

Innovatus Capital partners joins as a new investor; Scott Hutton joins as COO